Organogenesis Holdings is a regenerative medicine company focused on the development, manufacture and commercialization of solutions. Co.'s Advanced Wound Care products include Apligraf for the treatment of VLUs and DFUs; Dermagraft for the treatment of DFUs; PuraPly Antimicrobial (PuraPly AM) to address biofilm across various wound types; and Affinity and NuShield to address various wound sizes and types. Co.'s Surgical and Sports Medicine products include ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical application in targeted soft tissue repairs; and PuraPly AM for surgical treatment of open wounds. The ORGO stock yearly return is shown above.
The yearly return on the ORGO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ORGO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|